Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 5/20 | 0.43 |
| ▸ | CCR2 | P41597 | 6/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7897262 | 0.82 | GRIA2 (0.43) | GRIA2CCR2TRPV1 | |
| SCHEMBL7898940 | 0.82 | GRIA2 (0.58) | GRIA2CCR2TRPV1BDKRB1 | |
| SCHEMBL7898318 | 0.81 | GRIA2 (0.47) | GRIA2CCR2TRPV1BDKRB1 | |
| SCHEMBL11898515 | 0.79 | GRIA2 (0.70) | GRIA2CCR2TRPV1BDKRB1 | |
| SCHEMBL7899877 | 0.77 | HTR1A (0.44) | GRIA2CCR2TRPV1BDKRB1 | |
| SCHEMBL15338340 | 0.77 | CCR2 (0.40) | GRIA2CCR2TRPV1 | |
| SCHEMBL15327849 | 0.75 | TRPV1 (0.46) | GRIA2CCR2TRPV1BDKRB1 | |
| SCHEMBL7897498 | 0.75 | GRIA2 (0.46) | GRIA2CCR2TRPV1BDKRB1 | |
| SCHEMBL7897265 | 0.73 | GRIA2 (0.36) | GRIA2CCR2TRPV1BDKRB1 | |
| SCHEMBL7901349 | 0.73 | TACR1 (0.47) | CCR2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| EP-2417101-B1 | INDANE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-23 | — | — | EP | disclosed |
| EP-2417101-B1 | INDANE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-23 | — | — | EP | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| WO-2010115952-A1 | INDANE DERIVATIVES | N.V. ORGANON (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202781-A1 | INDANE DERIVATIVES | CHRNA5, CHRNA2, GRIK5 | GRIA2 24/4885CCR2 2756/4885TRPV1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.